Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study - Report - MDSpire

Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study

  • By

  • Graczyk Katarzyna

  • Dziewięcka Ewa

  • Winiarczyk Mateusz

  • Stępień Agnieszka

  • Przytuła Natalia

  • Holcman Katarzyna

  • Wiśniowska-Śmiałek Sylwia

  • Szot Wojciech

  • Kostkiewicz Magdalena

  • Rubiś Paweł

  • May 22, 2026

  • 0 min

Share

Clinical Report: Evaluating Risk Scores for Identifying ATTR-CA in AS

Overview

Expand on the implications of the eRAISE model's accuracy and the significance of the prevalence of ATTR-CA.

Background

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly recognized as a coexisting condition in patients with severe aortic stenosis (AS), complicating diagnosis and management. Accurate identification of ATTR-CA is crucial, as it can significantly impact treatment decisions and patient outcomes. The study highlights the need for effective screening tools to facilitate early diagnosis in this high-risk group.

Data Highlights

ParameterATTR-CA-AS (n=19)AS Only (n=85)
Age (years)82.6 ± 7.476 ± 6.9
Left Ventricular Ejection Fraction (%)44.654.7
NT-proBNP (pg/mL)4174.01238
Troponin (ng/L)59.623.3
Low-gradient/low-flow phenotype (%)73.7-

Key Findings

  • 18% of patients with severe AS were found to have concomitant ATTR-CA.
  • Patients with ATTR-CA-AS were significantly older and had more arrhythmic disorders.
  • Higher NT-proBNP and troponin levels were observed in patients with ATTR-CA-AS.
  • The eRAISE model showed the highest diagnostic accuracy (AUC=0.948) for detecting ATTR-CA.
  • No surgical aortic valve replacement was performed in the ATTR-CA-AS group during the follow-up period.

Clinical Implications

Healthcare professionals should consider the high prevalence of ATTR-CA in patients with severe AS when evaluating and managing these patients. Utilizing validated risk scores like the eRAISE model can enhance diagnostic accuracy and inform treatment strategies.

Conclusion

The coexistence of ATTR-CA in patients with severe AS is significant and warrants routine screening using effective diagnostic models to improve patient outcomes.

Related Resources & Content

  1. Clinical Research in Cardiology, 2025 -- Evaluating the RAISE Score in Postoperative Outcomes of Cardiac Transthyretin Amyloidosis Following Aortic Valve Replacement
  2. European Journal of Preventive Cardiology, 2025 -- Creation and assessment of the ASGARD risk score for effective monitoring of asymptomatic patients with mild aortic valve stenosis
  3. European Journal of Preventive Cardiology, 2025 -- Monitoring Strategies for Mild Aortic Stenosis: Adapting to Change in Clinical Practice
  4. Clinical Research in Cardiology, 2025 -- EASIX as a Prognostic Indicator for Three-Year Mortality in Patients with Aortic Stenosis Undergoing TAVR
  5. Concomitant transthyretin cardiac amyloidosis in patients undergoing TAVR for aortic stenosis: A systemic review and meta-analysis - ScienceDirect
  6. Concomitant transthyretin cardiac amyloidosis in patients undergoing TAVR for aortic stenosis: A systemic review and meta-analysis - ScienceDirect
  7. B26031 ATTR CCG Key Takeaways V1
  8. Cardiac transthyretin amyloidosis in aortic valve replacement: RAISE score performance in the postoperative setting | Clinical Research in Cardiology | Springer Nature Link

Original Source(s)

Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study

  • by Graczyk Katarzyna, Dziewięcka Ewa, Winiarczyk Mateusz, Stępień Agnieszka, Przytuła Natalia, Holcman Katarzyna, Wiśniowska-Śmiałek Sylwia, Szot Wojciech, Kostkiewicz Magdalena, Rubiś Paweł

  • May 22, 2026

Related Content

Recognizing the Transition to Advanced Heart Failure Earlier

Despite major advances in guideline-directed medical therapy (GDMT), worsening heart failure continues to drive significant morbidity, repeat hospitalizations and healthcare utilization worldwide.

  • by

  • May 27, 2026

  • 6 min
Validation of 2 Syncope Risk Scores and Comparison With Physician Risk Estimation

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors